European CHMP recommends approval of ranibizumab (Byooviz) for treatment of various ocular conditions
Byooviz is a biosimilar that has comparable quality, safety and efficacy to Lucentis (ranibizumab). It is available as a 10 mg/ml solution for injection as will be licensed for similar indications to Lucentis.
Source:
European Medicines Agency
SPS commentary:
It is unclear when a biosimilar version of ranibizumab will become available as the patent for Lucentis is likely to be in place until 2022.